Strategies for the identification of ubiquitin ligase inhibitors
Seth J Goldenberg1, Jeffrey G Marblestone, Michael R Mattern
1Progenra Inc., 271A Great Valley Parkway, Malvern, PA 19355, USA. goldenberg@progenra.com
Abstract:
Dysregulation of the UPS (ubiquitin-proteasome system) has been implicated in a wide range of pathologies including cancer, neurodegeneration and viral infection. Inhibiting the proteasome has been shown to be an effective therapeutic strategy in humans; however, toxicity with this target remains high. E3s (Ub-protein ligases) represent an alternative attractive therapeutic target in the UPS. In this paper, we will discuss current platforms that report on E3 ligase activity and can detect E3 inhibitors, and underline the advantages and disadvantages of each approach.
Insights
Dysregulation of the ubiquitin-proteasome system (UPS) is linked to diseases. Targeting E3 ligases offers a promising therapeutic strategy with potentially lower toxicity than proteasome inhibitors.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- The ubiquitin-proteasome system (UPS) is crucial for cellular protein homeostasis.
- UPS dysregulation is implicated in various pathologies, including cancer and neurodegenerative diseases.
- Proteasome inhibition is a validated therapeutic approach but associated with significant toxicity.
Purpose of the Study:
- To review current platforms for assessing E3 ligase activity.
- To identify methods for detecting E3 ligase inhibitors.
- To compare the advantages and disadvantages of different E3 ligase-targeting strategies.
Main Methods:
- Literature review of existing E3 ligase activity assays.
- Analysis of platforms for E3 inhibitor screening.
- Comparative assessment of assay methodologies.
Main Results:
- Several platforms exist for monitoring E3 ligase activity and identifying inhibitors.
- Each platform presents unique advantages and limitations regarding throughput, specificity, and cost.
- E3 ligases represent a viable alternative therapeutic target within the UPS.
Conclusions:
- E3 ligase-targeted therapies offer a promising alternative to proteasome inhibitors.
- Further development of robust screening platforms is essential for advancing E3 ligase-based drug discovery.
- Understanding the nuances of different assay platforms is critical for successful therapeutic development.
